Key result
Primary aldosteronism testing lacks quantitative outcome data in hypertensive patients with SLE.
Why the study?
Primary aldosteronism has not been investigated for its potential contribution to hypertension in patients with systemic lupus erythematosus.
Does primary aldosteronism testing identify secondary hypertension in hypertensive patients with SLE?
Observational
No
Does primary aldosteronism testing identify secondary hypertension in hypertensive patients with SLE?
This study investigates the potential contribution of primary aldosteronism to hypertension in patients with SLE.
Answers are grounded in this paper and cite their sources.
No quantitative data reported on PA testing in hypertensive SLE; leaves open whether screening identifies secondary hypertension in this population.
S L E is a chronic multisystem autoimmune disease in which cardiovascular disease is a leading cause of mortality, with a twofold to threefold greater risk than the general population. 1 Hypertension (HTN) is thought to contribute to this burden in patients with SLE, with a reported prevalence between 9% and 77%.1 The pathophysiology of HTN in SLE is not fully understood but is thought to relate to renal impairment, glucocorticoid treatment, chronic inflammation and/or disruption of the renin-angiotensin-aldosterone system.1 A major cause of secondary HTN, primary aldosteronism (PA), has not, however, been investigated for its potential contribution to HTN in SLE.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2025) conducted an observational in Hypertension in Systemic Lupus Erythematosus (SLE). Primary aldosteronism testing was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: